Given that the core pathological process of CTEPH is the abnormal growth and invasion of pulmonary artery smooth muscle cells, we speculated that when PLAUR is inhibited, the growth, invasion and metastasis of pulmonary artery smooth muscle cells are reduced, which can alleviate the development of CTEPH33. The gene discussed is PLAUR; the disease is chronic thromboembolic pulmonary hypertension.